Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with re

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about th

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic grow

Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solu

Henry Schein (HSIC) could produce exceptional returns because of its solid growth attributes.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

Bank of New York Mellon Corp purchased a new stake in Henry Schein, Inc. (NASDAQ: HSIC) in the undef

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Sc

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, b

Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascen

BTIG analyst David Larsen maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises the price ta

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings exe

Empowered Funds LLC lessened its stake in Henry Schein, Inc. (NASDAQ: HSIC) by 59.2% during the firs

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Barclays analyst Glen Santangelo maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raise

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the pri

Citigroup analyst Daniel Grosslight maintains Henry Schein (NASDAQ:HSIC) with a Buy and raises th

Henry Schein (NASDAQ:HSIC) reported second-quarter financial results on Tuesday. The transcript from

Henry Schein (NASDAQ:HSIC) raises FY2026 Adj EPS guidance from $5.23-$5.37 to $5.29-$5.39 vs $5.33 a

Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.27 per share which beat the analyst con

Piper Sandler analyst Jason Bednar maintains Henry Schein (NASDAQ:HSIC) with a Overweight and rai

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the pri

BMO Capital initiates coverage on Henry Schein (NASDAQ:HSIC) with a Market Perform rating and anno

Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a

Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on ana

BTIG analyst David Larsen upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Buy and announces $

Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to offi

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers the pri

Mizuho analyst Steven Valiquette maintains Henry Schein (NASDAQ:HSIC) with a Neutral and lowers t

Henry Schein (NASDAQ:HSIC) affirms FY2026 Adj EPS guidance from $5.23-$5.37 to $5.23-$5.37 vs $5.32

Henry Schein (NASDAQ:HSIC) reported quarterly earnings of $1.32 per share which beat the analyst con

Morgan Stanley analyst Erin Wright maintains Henry Schein (NASDAQ:HSIC) with a Underweight and ra

Top analysts change outlook on top names, check analyst ratings page for all changes. Keybanc initia

Citigroup analyst Daniel Grosslight initiates coverage on Henry Schein (NASDAQ:HSIC) with a Buy r

Evercore ISI Group analyst Elizabeth Anderson maintains Henry Schein (NASDAQ:HSIC) with a Outperf

Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office

Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30%

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:HSIC) with a Outperfor

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:HSIC) with a Neutral and raises the pri

JP Morgan analyst John Stansel maintains Henry Schein (NASDAQ:HSIC) with a Overweight and raises